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Abstract
Background: Pneumonia is the leading cause of child mortality worldwide. Streptococcus pneumoniae (SP) or
pneumococcus is estimated to cause 821,000 child deaths each year. It has over 90 serotypes, of which 7 to 13
serotypes are included in current formulations of pneumococcal conjugate vaccines that are efficacious in young
children. To further reduce the burden from SP pneumonia, a vaccine is required that could protect children from
a greater diversity of serotypes. Two different types of vaccines against pneumococcal pneumonia are currently at
varying stages of development: a multivalent pneumococcal conjugate vaccine covering additional SP serotypes;
and a conserved common pneumococcal protein antigen (PPA) vaccine offering protection for all serotypes.
Methods: We used a modified CHNRI methodology for setting priorities in health research investments. This was
done in two stages. In Stage I, we systematically reviewed the literature related to emerging SP vaccines relevant
to several criteria of interest: answerability; efficacy and effectiveness; cost of development, production and
implementation; deliverability, affordability and sustainability; maximum potential for disease burden reduction;
acceptability to the end users and health workers; and effect on equity. In Stage II, we conducted an expert
opinion exercise by inviting 20 experts (leading basic scientists, international public health researchers, international
policy makers and representatives of pharmaceutical companies). The policy makers and industry representatives
accepted our invitation on the condition of anonymity, due to sensitive nature of their involvement in such
exercises. They answered questions from CHNRI framework and their “collective optimism” towards each criterion
was documented on a scale from 0 to 100%.
Results: The experts expressed very high level of optimism (over 80%) that low-cost polysaccharide conjugate SP
vaccines would satisfy each of the 9 relevant CHNRI criteria. The median potential effectiveness of conjugate SP
vaccines in reduction of overall childhood pneumonia mortality was predicted to be about 25% (interquartile
range 20-38%, min. 15%, max 45%). For low cost, cross-protective common protein vaccines for SP the experts
expressed concerns over answerability (72%) and the level of development costs (50%), while the scores for all
other criteria were over 80%. The median potential effectiveness of common protein vaccines in reduction of
overall childhood pneumonia mortality was predicted to be about 30% (interquartile range 26-40%, min. 20%, max
45%).
Conclusions: Improved SP vaccines are a very promising investment that could substantially contribute to
reduction of child mortality world-wide.
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Pneumonia is the leading single cause of mortality in
children under the age of 5 years worldwide [1]. Many of
these pneumonia related deaths are vaccine preventable.
The global burden of disease of pneumococcal pneumo-
nia is difficult to determine, particularly in developing
countries with limited surveillance facilities and routine
health and health services data [2]. However a recent sys-
tematic review of disease burden in children under the
age of five reported that in 2000, an estimated 14.5 mil-
lion episodes of severe pneumococcal disease occurred,
causing 821,000 deaths [3]. Of these, 88,000 deaths
occurred among HIV positive children, of which 61%
were in 10 countries all located in Africa and Asia [3].
Streptococcus pneumoniae (SP) has at least 92 sero-
types. The most frequently used vaccine is the seven
valent, protein conjugate vaccine (Prevnar), protecting
against the serotypes that are most common in North-
ern America [2]. These serotypes account for only
approximately 39% of the invasive disease-causing sero-
types in Africa, 48% in Asia and 53.4% in Latin America
and the Caribbean, due to the biological diversity of
S. pneumoniae[4-6]. Additionally, replacement disease
[6] from non-vaccine serotypes has had varying effects
in different settings, including reports of emerging drug
resistance [1,2], on the effect of pneumococcal conjugate
vaccine (PCV) against overall invasive pneumococcal
disease, though the overall rates of antibiotic resistant
pneumococci have not increased following the introduc-
tion of PCV. Current ten- and thirteen-valent pneumo-
coccal conjugate vaccines that have obtained regulatory
approval worldwide contain over 70% of the estimated
invasive pneumococcal disease that is caused globally.
Eighty percent of global disease is caused by 17 sero-
types (95% CI 14-21) [7], and different serotypes predo-
minate in varying geographical regions [2], and differ in
prevalence among important clinical syndromes [8].
In order to prevent pneumonia infection due to any
serotype of S.pneumoniae there are two main vaccine
development strategies:
￿ a serotype-based PCV covering as high a proportion
as possible of all disease-causing serotypes. At the recent
International Symposium on Pneumococci and Pneumo-
coccal Diseases, Merck discussed further increasing vac-
cine valency by developing a 15-valent vaccine (Johnson
H, personal communication).P A T Hi sc u r r e n t l ys p o n -
soring emerging manufacturers to develop at least one
geographically tailored vaccine that will meet the pneu-
mococcal Advance Market Commitment (AMC). In
addition, with the AMC other vaccine manufacturers
may also be developing multi-valent pneumococcal con-
jugate vaccines with support from PATH (as announced
in the 2010 ISPPD);
￿ ap a n - s e r o t y p ep r o t e c t i v ev a c c i n eu s i n gc o n s e r v e d
common pneumococcal protein antigens (PPA) (combi-
nations of these two strategies are also under considera-
tion). Potential common protein vaccines are in phase 1
clinical trials, with other vaccine candidates in the pre-
clinical stages.
The aim of this briefing paper is to present the evi-
d e n c er e g a r d i n gk e yi s s u e ss u r r o u n d i n gt h ef i r s tt w o
vaccine development strategies and assess the level of
collective optimism among international experts con-
cerning the level of investment priority they feel is justi-
fied. The paper is presented as part of a series of papers,
each in turn focusing on different emerging vaccines
and other interventions against pneumonia.
Methods
We used a modified Child Health and Nutrition
Research Initiative (CHNRI) methodology for setting
priorities in health research investments. The methodol-
ogy has been described in detail [9-13] and implemented
in a variety of settings [14-18]. Briefly, the method uses
a set of pre-defined criteria and collects expert opinion
of all stakeholders on the risks and benefits associated
with investing in existing and/ or new interventions.
CHNRI exercise – stage I: Identification and selection of
studies
A literature search was conducted for each of the 9
CHNRI criteria (Figure 1): answerability, cost of develop-
ment, cost of product, cost of implementation, efficacy
and effectiveness, maximum potentail for disease burden
reduction, deliverability, affordability and sustainability,
acceptability to health workers, acceptability to the end
users and effect on equity [19]. Details about the search
strategies are presented in Additional File 1. The databases
Ovid MEDLINE (1950 to 2009), EMBASE (1980 to 2009)
and GLOBAL HEALTH (1973 to 2009) were searched. To
avoid database bias and to identify studies from developing
countries LILACS (Latin American and Caribbean Health
Sciences) and IndMed (Indian Medlars Centre) were also
searched but did not yield any additional citations. Addi-
tionally a grey literature database (SIGLE) and Cochrane
central register for controlled trials were also searched but
again did not yield any additional results. Searches were
conducted, and subsequently updated between the 16
th
March and 24
th May 2009, to ensure the most recently
published material was included. In order to ensure com-
pleteness, we also conducted hand searching of online
journals, scanned the reference list of identified citations,
and perused literature available on the websites of phar-
maceutical companies - Wyeth (later acquired by Pfizer),
GlaxoSmithKline and Intercell and international agencies
(GAVI, WHO, UNICEF and Pneumo ADIP)
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determined inclusion criteria. Included studies: (i) were
publications from developing countries and (ii) investi-
gated the effect, or distribution, coverage and delivery of
multivalent pneumococcal conjugate vaccines and/ or
cross-protective common protein vaccines, including
indirect effects of immunisation; or (iii) described the
global burden of disease of pneumococcal pneumonia in
children under 5; or (iv) were historical papers for com-
parison with the most recently published material.
Figure 1 A summary of Stage I of the CHNRI process of an evaluation of emerging intervention (a systematic review of the key CHNRI criteria).
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ing the effect of pneumococcal polysaccharide vaccine;
(ii) describing the global burden of disease in adults; (iii)
presenting delivery strategies for developed countries;
and (iv) describing the burden of only pneumococcal
otitis media and meningitis. Data from developed coun-
tries were used, when data from developing where not
available
CHNRI exercise – stage II: An expert opinion exercise
We shared the initial review of the literature with 20
experts that met during September 7-13, 2009 in
Dubrovnik, Croatia, to conduct the 2
nd stage of CHNRI
expert opinion exercise. They were chosen based on
their outstanding track record in childhood pneumonia
or pneumococcal disease research. We initially offered
participation to those experts with the greatest impact
of publications in their area of expertise over the past 5
years (for basic researchers and international public
health researchers), or to those that were affiliated with
the largest pharmaceutical company in terms of vaccina-
tion programme or international agency in terms of
their annual budget. For those who declined to partici-
pate (about 20%) replacements were found using the
same criteria. The process of second-stage CHNRI is
shown in Figure 2. All invited experts discussed the evi-
dence provided in CHNRI stage I, and then answered
questions from CHNRI framework (see Additional File
2). Their answers could have been “Yes” (1 point), “No”
(0 points), “N e i t h e rY e sn o rN o ” (0.5 points) or “Don’t
know” (blank). Their “collective optimism” towards each
criterion was documented on a scale from 0 to 100%.
The interpretation of this metric for each criterion is
simple: it is calculated as the number of points that
each evaluated type of emerging SP vaccine received
from 20 experts (based on their responses to questions
from CHNRI framework), divided by the maximum pos-
sible number of points (if all answers from all experts
are “Yes”).
Results
Details of the results of the literature search are pre-
sented in Additional File 1 For SP vaccines, 141
abstracts were considered and 14 papers were selected
for inclusion. Similarly, for common protein vaccines,
459 abstracts were considered and 7 papers were
selected for inclusion. Additional searches for deliver-
ability, equity and Global Burden of Disease were con-
ducted and 506 were selected for abstract screening, 21
of which were included in the review. In the following
paragraphs, the results of the literature search for each
criterion will be presented alongside a description of
how well the particular emerging intervention scored in
the CHNRI exercise.
Answerability
This was defined as achievement of a research goal of
the production of an effective novel vaccine that can be
fitted into the routine Expanded Programme of Immuni-
sation (EPI) schedule within in a time frame of 10 years.
Pneumococcal Conjugate Vaccine
PCVs are generally well tolerated and safe, including
when co-administered with other childhood vaccines.
They are formulated by conjugating multiple serotype-
specific capsular polysaccharide epitopes to a carrier pro-
tein [20]. PCV-7 and -13 formulations are conjugated to
cross reactive material 197 protein (CRM197), which is a
mutant diphtheria toxoid molecule. Most serotypes in
the PCV10 formulation are conjugated to protein D
derived from non-typeable Haemophilus influenzae
(NTHi) [21]. PCVs are immunogenic in children under
two years of age [20], whereas the polysaccharide vaccine
is not. The PCV7 was first licensed in February 2000 and
higher valency (10- and 13-) PCVs formulations have
been licensed since 2009. However, the possibility of add-
ing further serotypes appears to be limited, mainly
because the development cost is high and also because
the conjugation process and retaining of immunogenicity
for each of the included serotypes (which are not respon-
sible for a large proportion of disease) is complicated. In
addition, there is evidence showing a dampening of the
immunogenencity to select common serotypes in chil-
dren vaccinated with PCV13 compared to those vacci-
nated with PCV-7 [22,23]. This is possibly related to the
development of tolerance to vaccine components or
other interference by inclusion of multiple serotypes.
Some serotypes of S.pneumoniae more commonly
cause disease, and the prevalent causative serotypes also
vary geographically [24,25]. The current PCV7 covers
those serotypes found most commonly in North Amer-
ica, whereas PCV10 and 13 also include some serotypes
that are common in Africa as well as Asia. More
recently, consensus is being build over a set of 7 sero-
types that are common globally and a vaccine developed
containing these serotypes could provide serotype cover-
age closer to a 10 & 13 valent vaccine [6]. However, as
10 & 13 valent vaccines are already available, manufac-
tures have less incentive to develop such vaccines. A
geographically tailored vaccine covering fewer serotypes,
but specifically targeting those most prevalent in a given
area could also be an option. The cost of this makes it
an unlikely option, though. The issue of serotype “repla-
cement colonisation” would still remain. However, the
debate on serotype replacement has been complicated,
in some instances, by studies that have failed to distin-
guish serotype replacement of colonising bacteria in the
nasopharynx from replacement of those serotypes asso-
ciated with invasive disease, and whether these are actu-
ally the same [26].
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Page 4 of 14Presented with this evidence, the panel of experts
expressed a very high level of optimism (over 80%) on
the ability of PCV to satisfy the criterion of answerabil-
ity (Figure 3).
Common protein vaccine
In 1991, one of the first papers regarding a monoclonal
antibody against pneumococcal surface protein A (PspA)
was published [27]. It was shown to protect mice from
fatal pneumococcal infection, and it was thought that it
would be able to elicit a cross-protective response across
heterotypic pneumococcal strains [28]. There has been
ongoing research to identify other PPAs which either indi-
vidually or in combination may provide cross-protection
across different strains and serotypes of pneumococci [29].
Recently, novel antigens have been identified which
take advantage of the complete bacterial genome
sequence [30-32]. In late 2007 the lead vaccine candi-
dates serine/threonine protein kinase (StkP) and the
protein required for cell wall separation of group B
streptococcus (PcsB) were identified [33]. These were
found to be greater than 99.5% conserved among clinical
isolates and also cross-protective [27]. The antigens are
Figure 2 A summary of Stage II of the CHNRI process of an evaluation of emerging intervention (an expert opinion exercise using the CHNRI
criteria).
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Page 5 of 14immunogenic in both elderly and young children, the
serotype-independent expression will combat varying
strains and serotype distribution of pneumococci and
could potentially limit the emerging importance of non-
vaccine strains and serotypes of pneumococci [27].
There are other common protein antigen vaccine candi-
dates in pre-clinical trials.
Based on this evidence, the panel expressed concerns
over the ability of the pneumococcal protein vaccine
(PPV) to satisfy the answerability criterion (scored only
72%) when compared to the very high score (over 95%)
for PCV (Figure 4).
Efficacy - The impact of the vaccines under ideal
conditions
Pneumococcal conjugate vaccine
PCV7 has completed all clinical trial stages (Figure 5).
PCV7 is 82-97% efficacious against invasive pneum
Pneumococcal conjugate vaccines
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Figure 3 T h er e s u l t so fS t a g eI IC H N R Ip r o c e s s– an expert opinion exercise assessing the potential usefulness of investment in low-cost
pneumococcal conjugate vaccines.
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Page 6 of 14ococcal disease caused by vaccine serotypes, 90% effi-
cacious against vaccine-serotype specific pneumococ-
cal pneumonia and 57% efficacious against
pneumococcal acute otitis media caused by vaccine
serotypes [20].
PCV9 has also completed all clinical trial stages. How-
ever, it has not been developed further in favour of an
expanded 13-valent formulation (Figure 5). In a clinical
trial conducted in the Gambia the efficacy of PCV9 was
77% against invasive pneumococcal disease (IPD) caused
by vaccine serotypes, 50% against disease caused by all
serotypes, 15% against all-cause admissions and 16%
against all-cause childhood mortality [34]. This is an
important study as it is the largest of its kind to be
Common protein pneumococcal vaccines
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Page 7 of 14conducted in a developing country (with 17,436 children
participating in the study).
PCV10’s immunogenicity, safety and reactogenicity
profile is comparable to PCV7 [35]. Co-administration
studies have demonstrated its compatibility with major
childhood vaccines [36]. A phase III clinical trial found
that one month after dose 3, the percentage of subjects
with adequate antibody concentrations against each of
the pneumococcal serotypes was at least 96.6%, except
serotype 6B which was 79.3%, and those with sufficient
opsonophagocytic activity against each serotype was
98.0% [37]. In March 2009 GlaxoSmithKline received
European Commission authorisation for Synflorix™ -
their 10-valent PCV [21] - and received WHO prequali-
fication, a pre-requisite for supply to GAVI-eligible
countries, in November 2009 (Figure 5) [21].
There is limited published material regarding PCV13.
Phase I trials have found PCV13 to be more immunogenic
than the currently available 23vPS for most of the shared
serotypes in the two vaccines, and it is generally well toler-
ated [38,39]. There are ongoing phase II and III trials (Fig-
ure 5) [40]. In July 2009 Pfizer announced that the Chilean
Ministry of Health has become the first government
agency to approve Prevenar 13* Valent [41]. They were
granted European marketing authorisation for Prevenar
13* by the European Commission in December 2009 [42]
and by the US Food and Drug Administration [43].
Based on this evidence, the panel was optimistic that
all PCV vaccines would have a high likelihood of being
efficacious (Figure 3).
Common protein vaccine
In April 2009 Intercell announced that they are begin-
ning a phase I clinical trial of a vaccine containing three
conserved surface proteins StkP, PcsB and PSaA [44].
The vaccine formulation is currently being evaluated for
immunogenicity in different populations (Figure 6).
Mucosis and the University of Adelaide are currently
working on a common protein vaccine, but these are in
the pre-clinical stages and there is no published infor-
mation. Genocea Biosciences is working on T-cell anti-
gen discovery, again in the pre-clinical stages. Children’s
Hospital Boston is developing an inactivated whole cell
vaccine for phase 1 clinical trials. The aim is that it
would be low cost to manufacture, would require no
refrigeration and could be given orally or intranasally.
The University of Glasgow is developing pneumolysoid
f u s i o n sw h i c hw i l la c ta sa na n t i g e na n da d j u v a n tf o r
carried protein. It would provoke an immune response
after a single mucosal immunisation, and very small
amounts of protein would be required (Figure 6) [45].
In this case too, the panel felt that PPV would have a
high likelihood of efficacy (Figure 4).
Effectiveness - The impact of these vaccines in the
population
Pneumococcal conjugate vaccine
Introduction of PCV7 in America led to a reduction in
incidence of IPD of 69% in children under 1 year, 68%
in children aged 1-2 years, 44% in children aged 2-3
years, and no reduction was seen in those aged 3-4
years [20]. PCV7 has diminished hospitalisation rates for
all-cause pneumonia in young children by almost 40%
in America [46].
Oosterhuis-Kafeja and colleagues estimated that the
maximal achievable levels of theoretical serotype cover-
age of PCV 7 is 88.7% in North America and Australia,
and 77.6% in Europe, where serotypes 1 and 8 are more
prevalent [20]. They estimated though that the
Current Status
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7-valent PCV
Phase III P II P I
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Figure 5 The current status of the research into SP vaccines, as of
September 2009 (see Additional File 3 for details about the clinical
trials phases).
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Figure 6 The current status of the research into common protein
SP vaccines, as of September 2009 (see Additional File 3 for details
about the clinical trials phases.
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world - 67.3% in Africa, 63.4% in Latin America and
43.1% in Asia, as serotypes 1 and 5 are highly prevalent
in these regions. However, a recent study encompassing
data from 22 studies including 11,181 serotyped isolates
from children with invasive pneumococcal disease in
Africa concluded that the coverage of PSV 7 in Africa
was only 49%, whereas the coverage of a 10-valent vac-
cine, including types 1, 5 and 7F, would cover approxi-
mately 72% of invasive isolates from children, by
offering coverage against the additional serotypes 1, 5
and 7F [47].
PCV 9 was found to be 77-83% effective against IPD
by vaccine serotypes, and 36-50% protective against dis-
ease by all serotypes in HIV-uninfected children
[25,38,39]. HIV is major risk factor for pneumococcal
disease. Klugman and colleagues found that efficacy
declined from 65% to 38.8% in HIV positive children 6.2
years following immunisation with PCV9 [48]. A high
efficacy of 77.8% (95% CI 34.4, 92.5%) against vaccine
serotypes was maintained in non-infected children, how-
ever the overall efficacy against IPD due to any serotype
was only 35% (-30.6, 67.7%) [49]. Although PCV9 is
effective in HIV positive children, the immunogenicity
levels, persistence of antibodies and efficacy was lower
compared to HIV non-infected children. Nevertheless as
HIV infected children have a 40 fold greater burden of
pneumococcal disease, despite lower vaccine efficacy,
the absolute burden of IPD prevented was 18 fold
greater in HIV infected children compared to HIV non-
infected children [49,50].
Indirect immunity is protection in those who have not
been vaccinated, due to the reduced risk of pneumococ-
cus acquisition in vaccinated children, and interrupted
transmission thereof to other members of society. A
study in USA found that PCV 7 prevented twice as
many cases through indirect protection compared to the
direct effect of the vaccine in preventing IPD [51]. Colo-
nisation of the nasopharynx is a pre-requisite to devel-
oping pneumococcal disease, although the predictors of
who will develop disease following colonisation are less
well known [20]. PCV7 and PCV9 have both been
shown to reduce nasopharyngeal acquisition of pneumo-
coccus by some vaccine serotypes. Siblings of children
vaccinated with PCV9 were also less likely to become
colonised by the vaccine serotypes [20]. A recent Ameri-
can study found the contribution of indirect effects on
IPD to be around 20% of the total benefit in children
aged less than 5 [52].
A significant challenge of PCV vaccination targeting
only select serotypes is the potential for replacement
colonisation and disease occurring from non-vaccine
serotypes [19]. The long term effect of replacement
colonisation remains unclear, with differing experience
in Alaskan native, US and UK general populations.
Based on this evidence, the panel predicted the med-
ian potential effectiveness of SP vaccines towards reduc-
tion of overall pneumonia mortality would be about
25% (interquartile range 20-38%, min. 15%, max 45%)
(Figure 3).
Common protein vaccine
These vaccine candidates are in early trial stages, there-
fore no information is available regarding effectiveness
in the population. It is thought a vaccine will induce
herd immunity as animal models have found that select
protein vaccines reduce the risk pneumococcal colonisa-
tion [53]. It is also though that a protein vaccine will be
immunogenic in young children [53].
The panel predicted that the median potential effec-
tiveness of PPV in reducing overall pneumonia mortality
would be about 30% (interquartile range 26-40%, min.
20%, max 45%) (Figure 4).
Cost of development and implementation
Cost and securing sustainable production capacity are
major factors determining the deliverability of a vaccine.
In the case of a pneumococcal vaccine an “advanced
market commitment” (AMC) pilot has been established.
An AMC provides a demand led approach by stimulat-
ing private investment in vaccine research and develop-
ment, and increasing manufacturing capacity for
vaccines which primarily address diseases of developing
countries [54]. AMC donors guarantee the price of spe-
cific vaccines, aiming to reduce the time delay between
the introduction of new vaccines into developed and
developing countries. Through a legally binding con-
tract, AMC participating companies commit to continu-
ously supply the vaccines at lower and sustainable price
to GAVI countries for a 10 year period [6,54].
While the panel was optimistic about the development
of a low cost PCV, it expressed concern over the ability
to develop a PPV with similarly low development costs
(Figure 3 and Figure 4).
Deliverability
It has been demonstrated that adequate infrastructure in
the form of cold chain equipment, functioning health
systems reinforced by refresher training of health work-
ers, ongoing monitoring and periodic evaluations of vac-
cine coverage, surveillance systems to capture adverse
events following immunization, and activities to generate
high levels of awareness in the community are the keys
to the successful deliverability of any new vaccine [55].
The deliverability of such a vaccine is enhanced if it can
be integrated into the existing Expanded Programme of
Immunization (EPI) schedules [56].
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Since PCV 7 does not tolerate freezing, it should be
stored at 2-8°C, and therefore requires a cold chain,
similar to the current EPI vaccines [52]. Other PCVs
currently in production are likely to have similar cold
chain requirements, as they use a similar vaccine tech-
n o l o g y .P C V- 7 ,- 1 0a n d- 1 3f i ti nt ot h ec u r r e n tE P I
schedule, and can be given at 6, 10 and 14 weeks.
Although PCV 7 is safe to be co-administered alongside
other vaccinations, an alternative body site is preferable
[52]. In stage II of the modified CHNRI exercise, the
experts were highly optimistic regarding the deliverabil-
ity of PCV7 and thus scored it high on deliverability,
with CHNRI score for this criterion greater than 80%
(Figure 3).
Common protein vaccine
The specific delivery requirements of a common protein
vaccine are unknown, as the trials are in very early
stages. If other protein vaccines are used for comparison
it is likely the vaccine will require refrigeration. The
panel was optimistic regarding the deliverability of this
vaccine, again with CHNRI score greater than 80%
(Figure 4).
Global burden of disease and disease burden reduction
Pneumococcal conjugate vaccine
Immunisation is the most effective method available to
reduce morbidity and mortality from infectious diseases
[2]. After introduction of Hib vaccine in Kenya, the pre-
valence of disease fell by 88% in three years [57]. This
shows the dramatic impact an effective vaccine can have
on disease burden, even in a developing country setting.
The underlying aim behind SP vaccine development
approaches is that they will prevent infection by S.pneu-
moniae. It will not however protect neonates or children
under 6 weeks of age if delivered within the existing
child EPI schedule. Any indirect effects of the vaccine
may have protective effect in this age group. Neonates
and young infants are at risk of certain bacterial infec-
tions, including pneumococcal disease, but the incidence
has not been clearly defined [58]. Between age 6 and 24
months is when the incidence of disease is at its highest
[59]. In an American study comparing rates of pneumo-
coccal infection before and after the introduction of
PCV7, it was found that in infants aged 0 to 60 days the
rate of IPD decreased from 7.3 per 100.000 live births to
4.2 per 100.000 live births [58]. This suggests that neo-
nates and infants currently too young to receive PCV7,
along with non-immunised members of the community,
are benefiting from indirect protection [58]. Conjugate
v a c c i n e sm a ye v e nb ea b l et oi n d u c eh e r di m m u n i t yi n
situations where coverage is significantly incomplete,
and fewer than the recommended number of doses have
been administered [60]. Major problems encountered
when treating Streptococcus pneumoniae infection espe-
cially in least developed countries is poor access to cura-
tive health-care and antibiotic resistance [59], therefore
prevention with a vaccine is better than trying to cure
the disease.
The potential disease burden reduction with PCV7 has
not been maximised as it has yet to be distributed
throughout most of Africa and Asia. PCV7 covers
approximately 40-60% of the serotype distribution in
Africa and Asia, where the majority of child deaths
occur. If delivered at high immunization coverage levels,
it has the potential to reduce deaths by approximately
50% - not including (positive and negative) indirect
effects - which would save around 400,000 lives per year
(assuming 100% of vaccine efficacy). Distributing
PCV10, with higher disease coverage of 60 to 80%, has
the capacity to increase that number to around 550,000,
again not including (positive and negative) indirect
effects.
Introducing a new vaccine can potentially also
enhance delivery of existing vaccines [2] and increase
coverage and uptake of vaccines generally [61]. This
effect would contribute to a reduction in the burden of
all vaccine preventable diseases but the reduction
depends upon an array of systems issues that occur
whether service delivery occurs in health facility, by out-
reach, or in the community.
Common protein vaccine
It is estimated that there are over 800,000 deaths from
SP per year in children under age 5. Therefore, if the
new PPV would indeed be 100% effective against all
pneumococci world-wide, then it would have the
potential to reduce disease burden by 100%, thus pre-
venting avoiding 800,000 deaths per year. However, the
assumptions are 100% immunization coverage (or
enough to induce indirect protection) and quality con-
trol of the delivery of this vaccine in all settings. There
are large problems with delivery in the most remote
and poor settings, ranging from the breakdown of the
cold chain to inadequate administration of the vaccine.
Even when a vaccine attains high coverage, the last to
be reached are often in the poorest areas which house
a higher proportion of the disease burden, and chil-
dren less than 6 weeks old only gain protection
through herd immunity. In reality, the achievable dis-
e a s eb u r d e nr e d u c t i o ni nc h i l d r e nu n d e ra g e5w o u l d
surely be less than that.
The expert group felt that both the pneumococcal
conjugate vaccines and the common protein vaccines
had high median potential effectiveness for reduction of
pneumonia mortality (25%; interquartile range 20-38%
and min. 15%, max 45%; and 30%; interquartile range
26-40% and min. 20%, max 45%, respectively) (Figures 3
and 4).
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Pneumococcal conjugate vaccine
The distribution of communicable diseases globally
highlights the inequity amongst the various population
groups. Communicable diseases account for 68% of dis-
ease burden in Africa but only 7% in developed coun-
tries [54]. If this gap were reduced, much of the global
difference in life expectancy and mortality would disap-
pear. Even within a country, it is the poor and vulner-
able who have reduced access to heath care and who
experience a higher burden of disease [62]. Cunha and
colleagues have shown that it is the children from low
socio-economic strata living in developing countries
who appear to be at the highest risk for acute lower
respiratory tract infections [63]. Victora and colleagues
have demonstrated an inverse relationship between
social class and maternal education with the risk of
developing pneumonia [64]. The economic conse-
quences of pneumonia, including cost to family and the
resulting disability, the economic pressure on develop-
ing governments and on struggling health systems lead
to a cycle of poverty, further widening the gap of
inequity [2].
The panel was optimistic that a highly effective conju-
gate vaccine against the pneumococcus would have a
profound impact on decreasing child health inequity
and would be accepted by the end-users and the health
workers, with a score for each of these criteria greater
than 90% (Figure 3).
Common protein vaccine
The panel was optimistic that a highly effective common
protein vaccine against the pneumococcus would have a
profound impact on decreasing child health inequity
and would be accepted by the end-users and the health
workers, with a score greater than 90%, and these scores
were the same as for PCV (Figure 4).
Discussion
The literature review summarized in this paper presents
the available evidence required for making an informed
decision on emerging pneumococcal vaccines to set
research priorities. The score of both PCV and PPV
against the criteria is the collective optimism of a panel
of experts drawn from varying backgrounds. We have
shown that both a multivalent pneumococcal conjugate
vaccine covering all serotypes and a cross-protective
common protein vaccine have the potential to signifi-
cantly reduce the burden of pneumococcal disease in
children under age 5 years. It is unlikely a vaccine cov-
ering all serotypes will be developed. Cross-protective
common protein vaccines are currently being investi-
gated as alternate or synergistic strategies to improve
the coverage against a broader diversity of pneumococ-
cal serotypes.
Developing countries in general, and the poorer popu-
lations within them specifically, account for the greatest
burden of disease due to pneumonia globally. An effec-
tive vaccine distributed worldwide will reduce that bur-
d e n ,a n di fd e l i v e r yi st a r g e t e da tt h ep o o r e s ta r e a s ,t h e
gap of inequity in health will also be reduced.
While both types of vaccine appear to score well over-
all and are likely to have a high impact on reduction of
disease burden and equity, the experts were not very
optimistic about the feasibility (answerability) of the
PPV. However, given that it is unlikely to develop a low
cost PCV covering all serotypes, it may be worthwhile
focussing on developing a low cost PPV. A limiting fac-
t o ri st h a tt h ee x p e r t sf e l tt h a tt h ed e v e l o p m e n tc o s to f
a PPV is unlikely to be low, so though we may even-
tually develop such a vaccine, it might not be affordable
for resource-poor developing countries to introduce the
vaccine without active support of international agencies
like the GAVI Alliance.
One of the factors influencing efficacy estimates is the
poor ability to actually identify the bacterial aetiology.
Currently most of the aetiology-specific diagnosis is
based on looking at reduction in pneumonia and “clini-
cal or radiological signs”. However this can be very con-
fusing. For example, it is known that a proportion of
children with RSV pneumonia will have clinical chest
radiographs consistent with lobar pneumonia, which can
be confused with a bacterial pneumonia, like pneumo-
coccus [65]. Therefore, evaluation of diagnostics that do
not require samples from within the lung, yet may be
more sensitive than blood culture isolation, would be an
aid to monitoring vaccine impact on IPD. These can be
used inter-alia in studies estimating burden of disease
studies as well as vaccine effectiveness and will help
accurately interpret the impact of a vaccine.
This is the first time such an exercise has been
attempted to predict the impact of emerging vaccines.
CHNRI methodology was primarily designed to evaluate
existing interventions and competing investment priori-
ties for health research. Though we used the CHNRI
criteria, we modified it by including systematic review of
available literature and not involving all stakeholders (e.
g. end-users and health workers). The scores included
herewith express the collective opinion of a panel of 20
experts. There is always an element of uncertainty while
predicting impact of interventions which do not exist
and have no clinical trial data to support them. While
we feel that the results would be reproducible with
another panel of a similar composition in a different set-
ting, this is a hypothesis that can be tested.
Conclusions
To summarize, while it is not only important that
investments are made in researching new vaccines,
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cated for proper distribution of the vaccine. Without
adequate attention to these very real contextual factors
and health systems issues, even the best investments can
fail. Until that happens, we will see little reduction in
the 800,000 child deaths per year due to pneumococcal
pneumonia.
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